News

SEMA4 PRESS RELEASE | 09.11.17

Scientists at Sema4 and Mount Sinai Construct First Predictive Model of Inflammatory Bowel Disease

“Scientists at the Icahn School of Medicine at Mount Sinai, Sema4, and collaborating institutions today published results of an in-depth, multi-’omics approach to characterizing the immune component of inflammatory bowel disease (IBD). These results provide new insights into the biologic networks involved in IBD with potential to identify new targets and eventually novel interventions for the treatment of patients living with IBD…”
READ MORE
HUMAN PROOF OF CONCEPT | 08.31.17

Giving It His Best Schadt

“Eric Schadt may enjoy the simple things in life — high velocity, a good polo shirt — but he is the first to admit that life is not simple. Living things are such complex systems, in fact, that our best chance to promote wellness is to understand them as vast information networks…”
READ MORE
SEMA4 PRESS RELEASE | 08.10.17

Alexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology

“Alexion Pharmaceuticals, Inc. and Sema4 today announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion’s rare disease SmartPanel analytics with Sema4’s proven success in next-generation sequencing and genomic interpretation to further enable novel diagnostic and therapeutic insights into rare diseases…”
READ MORE
GENOMEWEB | 07.26.17

Helix Launches Genomics App Store, But Will Consumers Pay?

“The launch of Helix’s online marketplace of applications this week might signal a new era in consumer genomics, but while developers jump in with a variety of products they hope will entice customers, questions remain as to who those customers will be and whether they’ll regularly engage with these apps. Among the initial crop of products offering insights into health, family planning, ancestry, fitness, nutrition, and some entertainment…”
READ MORE
BIOSPECTRUM | 07.25.17

Sema4 Announces the Launch of CarrierCheck

“Sema4, an interdisciplinary health information company focused on empowering people to take charge of their health and data, announced the launch of CarrierCheck, a simple saliva-based test that provides individuals with a snapshot of how their DNA may affect their future children…”
READ MORE
SICKLE CELL ANEMIA NEWS | 07.25.17

Sema4 and Helix Launch CarrierCheck, a Genetic Screen of 67 Hereditary Diseases

“Sema4, an interdisciplinary health information company, has partnered with Helix, a personal genomics company, to launch CarrierCheck — a simple, saliva-based test that screens for 67 conditions, including sickle cell disease (SCD). The test may provide individuals with a snapshot of how their DNA may affect their future children or it may increase their awareness of their own genetic history…”
READ MORE
SEMA4 PRESS RELEASE | 07.24.17

Sema4 Partners with Helix to Launch CarrierCheck™: A New, Easy Way for Consumers to Access a Genetic Screen for 67 Hereditary Diseases

“Sema4 today announced the launch of CarrierCheck, a simple saliva-based test that provides individuals with a snapshot of how their DNA may affect their future children. CarrierCheck is the only carrier test that screens for 67 conditions that can be ordered by consumers online. It was developed in collaboration with Helix, a personal genomics company that today launched the first online marketplace for DNA-powered products…”
READ MORE
FORBES | 07.24.17

Helix Bets An ‘App Store’ Can Make Consumers Care About Their DNA

“Is the key to getting people to want their genetic data making the experience more like the Apple App Store? That’s the bet being made by Helix, a personal genomics company spun out of Illumina, the leader in making DNA sequencers…”
READ MORE
WIRED | 07.24.17

Helix’s Bold Plan to Be Your One Stop Personal Genomics Shop

“Sema4 announced a new, less expensive test on Helix’s marketplace that identifies genetic indications for only 67 diseases, which you can order yourself from the comfort of your home—with a small caveat…”
READ MORE
SEMA4 PRESS RELEASE | 06.27.17

Sema4 and GNS Healthcare Announce Collaboration Using REFS™ Causal Machine Learning and Simulation AI Platform

“Sema4 and GNS will collaborate to maximize various data resources, such as longitudinal EMR records, next generation sequencing, proteomics, and other ‘omic data, to discover underlying drivers of cardiovascular disease. These insights may help identify existing treatments for cardiovascular conditions, as well as identify opportunities for the research and development of next-generation treatments….”
READ MORE